

10/560853

IAP20 RECEIVED TO 08 DEC 2005

Attorney's Docket No. 049542/303320

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Wilson *et al.*

Attn: DO/US

International Appl. No.: PCT/US2004/018171

International Filing Date: 7 June 2004

For: A₁ ADENOSINE RECEPTOR ANTAGONISTS

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

A list of references is provided on the attached PTO-1449 including those cited in the International Search Report of corresponding International Application No. PCT/US2004/018171. A copy of the Search Report is enclosed for the Examiner's convenience. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


The Examiner may wish to consider the notations on the Search Report itself regarding the relevance of each item. It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,



Michelle L. Cunningham
Registration No. 51,072

ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260
Customer No. 00826

"Express Mail" Mailing Label Number EV395776909US
Date of Deposit: December 8, 2005
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, Alexandria, VA 22313-1450.

Pamela Lockley

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	To Be Assigned 10/560853
				Filing Date	Concurrently Herewithin
				First Named Inventor	Wilson
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	5	Attorney Docket Number	049542/303320

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-2,887,486	05-19-1959	Leake <i>et al.</i>	
	2	US-3,031,451	04-24-1962	Schlesinger <i>et al.</i>	
	3	US-3,309,271	03-14-1967	Georges <i>et al.</i>	
	4	US-3,317,533	05-02-1967	De Ridder	
	5	US-3,961,060	06-01-1976	Fuxe	
	6	US-4,092,417	05-30-1978	Credner <i>et al.</i>	
	7	US-4,299,832	11-10-1981	Brown <i>et al.</i>	
	8	US-4,378,359	03-29-1983	Chiodoni <i>et al.</i>	
	9	US-4,548,818	10-22-1985	Kjellin <i>et al.</i>	
	10	US-4,612,315	09-16-1986	Jacobson <i>et al.</i>	
	11	US-4,622,324	11-11-1986	Klessing <i>et al.</i>	
	12	US-4,696,932	09-29-1987	Jacobson <i>et al.</i>	
	13	US-4,769,377	09-06-1988	Snyder <i>et al.</i>	
	14	US-4,772,607	09-20-1988	Badger <i>et al.</i>	
	15	US-4,868,186	09-19-1989	Franzone <i>et al.</i>	
	16	US-4,968,672	11-06-1990	Jacobson <i>et al.</i>	
	17	US-4,971,972	11-20-1990	Doll <i>et al.</i>	
	18	US-5,032,593	07-16-1991	Rzeszotarski <i>et al.</i>	
	19	US-5,066,655	11-19-1991	Olsson	
	20	US-5,068,236	11-26-1991	Suzuki <i>et al.</i>	
	21	US-5,208,240	05-04-1993	Peet <i>et al.</i>	
	22	US-5,248,770	09-28-1993	Jacobson <i>et al.</i>	
	23	US-5,256,650	10-26-1993	Peet <i>et al.</i>	
	24	US-5,296,463	03-22-1994	Lee <i>et al.</i>	
	25	US-5,298,508	03-29-1994	Jacobson <i>et al.</i>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	To Be Assigned 10/560853
				Filing Date	Concurrently Herewithin
				First Named Inventor	Wilson
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	5	Attorney Docket Number	049542/303320

U. S. PATENT DOCUMENTS					
	26	US-5,314,890	05-24-1994	Agostini <i>et al.</i>	
	27	US-5,340-813	08-23-1994	Klein <i>et al.</i>	
	28	US-5,395,836	03-07-1995	Shimada <i>et al.</i>	
	29	US-5,434,150	07-18-1995	Austel <i>et al.</i>	
	30	US-5,447,933	09-05-1995	Suzuki <i>et al.</i>	
	31	US-5,532,368	07-02-1996	Kufner-Muhl <i>et al.</i>	
	32	US-5,543,415	08-06-1996	Suzuki <i>et al.</i>	
	33	US-5,545,627	08-13-1996	Jacobson <i>et al.</i>	
	34	US-5,719,279	02-1998	Kufner-Muhl	
	35	US-5,786,360	07-1998	Neely	
	36	US-2002/0058667	05-16-2002	Castelhano <i>et al.</i>	
	37	US-2002/0082269 A1	06-27-2002	Neely	
	38	US-2004/0014766 A1	01-22-2004	Dunten <i>et al.</i>	
	39	US-2005/0119258 A1	06-02-2005	Wilson <i>et al.</i>	
	40	US-2005/0187226 A1	08-25-2005	Wilson <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	41	BE 636 828 A	03-02-1964	MR A.H.E. GEORGES		
	42	GB 947,495	01-22-1964	RIDDER		
	43	DE 1 245 383	07-27-1967	DE RIDDER		
	44	DE 26 59 241	07-06-1978	KLOSA		
	45	EP 0 501 379 A2	09-02-1992	KYOWA HAKKO KOGYO CO., LTD.		
	46	EP 0 503 563 A2	09-16-1992	MERRELL DOW PHARMACEUTICA LS INC.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	To Be Assigned 10/560853
				Filing Date	Concurrently Herewithin
				First Named Inventor	Wilson
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	3	of	5	Attorney Docket Number	049542/303320

FOREIGN PATENT DOCUMENTS						
	47	EP 0 764 647 A1	03-26-1997	BAYER AG		
	48	FR 2 483 922	11-12-1981	DE RIDDER		
	49	WO 2003/028730 A2	04-10-2003	NORVATIS AG		
	50	WO 2004/074247 A2	09-02-2004	ENDACEA, INC		
	51	WO 2004/110379 A2	12-23-2004	ENDACEA, INC		

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	52	ABBRACCHIO, M.P. and F. CATTABENI, "Selective Activity of Bamifylline on Adenosine A ₁ -Receptors in Rat Brain," <i>Pharmacological Research Communications</i> , 1987, pp. 537-545, Vol. 19(8).	
	53	BEAUGLEHOLE, A.R., <i>et al.</i> , "Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A ₁ -Adenosine Receptor," <i>J. Med. Chem.</i> , 2000, pp. 4973-4980, Vol. 43.	
	54	BEAUGLEHOLE, A.R., <i>et al.</i> , "New Irreversible Adenosine A ₁ Antagonists Based on FSCPX," <i>Bioorganic and Medicinal Chemist Letters</i> , 2002, pp. 3179-3182, Vol. 12.	
	55	BELARDINELLI, L., <i>et al.</i> , "1, 3-Dipropyl-8-[2-(5, 6-Epoxy)Norbomyl]Xanthine, a Potent Specific and Selective A ₁ Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT ₁ MF-2 Cells," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 1995, pp. 1167-1176, Vol. 276 (2).	
	56	BELLIARDO, F. and C. LUCARELLI, "Micro-Scale Liquid Chromatographic Method for the Determination of Bamifylline and its Major Metabolite in Human Plasma," <i>Journal of Chromatography</i> , 1990, pp. 305-309, Vol. 535.	
	57	CARLUCCI, G., <i>et al.</i> , "Determination of Bamifylline Hydrochloride Impurities in Bulk Material and Pharmaceutical Forms Using Liquid Chromatography with Ultraviolet Detection," <i>Journal of Pharmaceutical & Biomedical Analysis</i> , 1990, pp. 1067-1069, Vol. 8.	
	58	FOLEY, L.H. <i>et al.</i> , "Modified 3-Alkyl-1, 8-dibenzylxanthines as GTP-Competitive Inhibitors of Phosphoenolpyruvate Carboxykinase," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2003, pp. 3607-3610, Vol. 13.	
	59	HESS, S., "Recent Advances in Adenosine Receptor Antagonist Research," <i>Expert Opin. Ther. Patents</i> , 2001, pp. 1533-1561, Vol. 11 (10).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	To Be Assigned 10/560853
				Filing Date	Concurrently Herewithin
				First Named Inventor	Wilson
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	4	of	5	Attorney Docket Number 049542/303320	

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	60	JACOBSON, K.A., <i>et al.</i> , "A Functionalized Congener Approach to Adenosine Receptor Antagonists: Amino Acid Conjugates of 1,3-Dipropylxanthine," <i>Molecular Pharmacology</i> , 1985, pp. 126-133, Vol. 29.	
	61	JACOBSON, K.A., <i>et al.</i> , "Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential," <i>Journal of Medicinal Chemistry</i> , February 1992, pp. 407-422, Vol. 35(3).	
	62	KURODA, S., <i>et al.</i> , "Design, Synthesis and Biological Evaluation of a Novel Series of Potent, Orally Active Adenosine A ₁ Receptor Antagonists with High Blood-Brain Barrier Permeability," <i>Chem. Pharm. Bull.</i> , 2001, pp. 988-998, Vol. 49.	
	63	MÜELLER, C.E., <i>et al.</i> , "7-Deaza-2-phenyladenines: Structure-Activity Relationships of Potent A ₁ Selective Adenosine Receptor Antagonists," 1990, pp. 2822-2828, Vol. 33(10).	
	64	NEELY, C.F., <i>et al.</i> , "A ₁ Adenosine Receptor Antagonists Block Ischemia-Reperfusion Injury of the Heart," <i>AHA-Circulation</i> , November 1996, pp. 1-5, 94(9).	
	65	NICOT, G. and G. LACHATRE, "High-Performance Liquid Chromatographic Method for the Determination of Bamifylline and its Three Metabolites in Human Plasma," <i>Journal of Chromatography</i> , 1983, pp. 239-249, Vol. 277.	
	66	NOVELLINO, E., <i>et al.</i> , "Design, Synthesis and Biological Evaluation of Novel <i>N</i> -Alkyl- and <i>N</i> -Acyl-(7-substituted-2-phenylimidazo[1,2- <i>a</i>] [1,3,5] triazin-4-yl) amines (ITAs) as Novel A ₁ Adenosine Receptor Antagonists," <i>J. Med. Chem.</i> , 2002, pp. 5030-5036, Vol. 45.	
	67	PATEL, A. <i>et al.</i> , "I-BW-A844U, an Antagonist Radioligand with High Affinity and Selectivity for Adenosine A ₁ Receptors, and ¹²⁵ I-Azido-BW-A844U, a Photoaffinity Label," <i>Molecular Pharmacology</i> , 1988, pp. 585-591, Vol. 33.	
	68	SACCHI, A., <i>et al.</i> , "Research on Heterocyclic Compounds. PartXXXVI. Imidazo[1,2- <i>a</i>]pyrimidine-2-acetic derivatives: synthesis and anti-inflammatory activity," <i>Eur. J. Med. Chem.</i> , 1997, pp. 677-682, Vol. 32.	
	69	SCAMMELLS, P.J., <i>et al.</i> , "Substituted 1,3-Dipropylxanthines as Irreversible Antagonists of A ₁ Adenosine Receptors," <i>J. Med. Chem.</i> , 1994, pp. 2704-2712, Vol. 37.	
	70	SCHIANTARELLI, P., <i>et al.</i> , "Evidence of Pulmonary Tropism of Bamifylline and its Main Active Metabolite," <i>Arzneim.-Forsch/Drug Res.</i> , 1989, pp. 215-219, Vol. 39.	
	71	VAN GALEN, P.J.M., "Adenosine A ₁ and A ₂ Receptors: Structure-Function Relationships," <i>Medicinal Research Reviews</i> , 1992, pp. 423-471, Vol. 12.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				10/560853	
				Application Number	To Be Assigned
				Filing Date	Concurrently Herewithin
				First Named Inventor	Wilson
				Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned				
Sheet	5	of	5	Attorney Docket Number	049542/303320

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	72	VAN GALEN, P.J.M., <i>et al.</i> , "A Model for the Antagonist Binding Site on the Adenosine A ₁ Receptor, Based on Steric, Electrostatic, and Hydrophobic Properties," <i>J. Med. Chem.</i> , 1990, pp. 1708-1713, Vol. 33(6).	
	73	VAN MUJLWIJK-KOEZEN, J. E., <i>et al.</i> , "Synthesis and Use of FSCPX, an Irreversible Adenosine A ₁ Antagonist, as a 'Receptor Knock-Down' Tool," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2001, pp. 815-818, Vol. 11.	
	74	VAN RHEE, A.M., <i>et al.</i> , "Tetrahydrobenzothiophenone Derivatives as a Novel Class of Adenosine Receptor antagonists," <i>J. Med. Chem.</i> , 1996, pp. 398-406, Vol. 39(2).	
	75	VAN TILBURG, E.W., <i>et al.</i> , "Substituted 4-Phenyl-2-(phenylcarboxamido)-1,3-thiazole Derivatives as Antagonists for the Adenosine A ₁ Receptor," <i>Bioorganic & Medicinal Chemistry Letters</i> , 2001, pp. 2017-2019, Vol. 11.	
	76	WILSON, C.N., <i>et al.</i> , "Lipopolysaccharide Binds to and Activates A ₁ Adenosine Receptors on Human Pulmonary Artery Endothelial Cells," <i>Journal of Endotoxin Research</i> , 2002, pp. 263-271, Vol. 8 (4).	
	77	WINDHOLZ, M., ed., "Bamethan," <i>The Merck Index</i> , 1983, p. 138, Tenth Edition, Merck & Co., Inc., Rahway, N.J.	
	78	"Communications to the Editor," <i>J. Med. Chem.</i> , 1992, pp. 3578-3581, Vol. 35(19).	
	79	"Other News to Note," <i>BioWorld Today</i> , March 1996, p. 2.	

RTA01/2194750v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.